Lobbying Information
Subject Matters
- Health
- Industry
- Intellectual Property
- International Trade
- Justice and Law Enforcement
- Privacy and Access to Information
- Science and Technology
Subject Matter Details
Legislative Proposal, Bill or Resolution
- Comprehensive Economic Trade Agreement with Europe (CETA) and pharmaceutical intellectual property protection.
- Health Canada's enforcement of Canada's Food and Drugs Act and Regulations as they relate to the cross border sale of drugs to the United States.
Legislative Proposal, Bill or Resolution, Policies or Program
- The House of Commons Standing Committee on Health's (HESA) and the Standing Committee on Social Affairs review of the 2004-2014 Health Accord and renegotiation of the 2014 Health Accord
Policies or Program
- Canada's Access to Medicines Regime. Continued conversation with parliamentarians regarding the work the Johnson & Johnson does in Africa and developing countries providing medicines and treatments
- Input into the Patented Medicines Price Review Board evaluation of annual Research and Development investments by companies in Canada based on SR&ED tax rules. Working with PMPRB and legislators to ensure appropriate measures of R&D investment are in place.
Regulation
- An amendment to the Patented Medicines (Notice of Compliance) Regulations ("PM(NOC) Regulations") regarding the right to appeal.
- Health Canada's proposal to add the drug tramadol to the Schedule of the Narcotic Control Regulations (NCR) with regard to changing the status of this prescription product to a controlled substance and the scheduling process for new products
- Modernization of Food & Drug Act: support for proposed regulatory changes, modernization and international harmonizations with other regulatory bodies (EMA/FDA).
- Subsequent Entry Biologics (SEBs): the need for regulatory amendments to facilitate their approval.
Communication Techniques
-
Written communication
-
Oral communication
Government Institutions
-
Finance Canada (FIN)
-
Foreign Affairs and International Trade Canada (DFAITC)
-
Health Canada (HC)
-
House of Commons
-
Industry Canada
-
Justice Canada (JC)
-
Members of the House of Commons
-
Patented Medicine Prices Review Board (PMPRB)
-
Prime Minister's Office (PMO)
-
Senate of Canada
In-house Corporation Details
Description of activities
Research based bio-pharmaceutical company
Resarch and development, sales and marketing of innovative drugs
Responsible officer name and position during the period of this registration
Chris Halyk,
General Manager
Government funding
No government funding was received during the last completed financial year.
In-house Corporation Contact Information
Address:
19 Green Belt Drive
Toronto, ON M3C 1L9
Canada
Telephone number:
416-449-9444
Fax number:
416-449-2658
Parent Company Information
- Johnson & Johnson
-
One Johnson & Johnson Plaza
New Brunswick, NJ 08933
United States of America
Subsidiary Beneficiary Information
Janssen Inc. does not have any subsidiaries that could have a direct interest in the outcome of the undertaking
Lobbyists Details
Senior Officers whose lobbying activities represent less than 20% of their Duties
- Julia Brown,
VP Patient Access |
No public offices held
- Cathy Lau,
VP Regulatory Affairs |
No public offices held
- Veera Rastogi,
VP Law |
Public offices held
Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties
- Mark Fleming,
Director, Federal Affairs & Health Policy |
No public offices held
